Role of Ranolazine in cardiovascular disease and diabetes: Exploring beyond angina

被引：18
作者：
Banerjee, Kinjal [1 ]
Ghosh, Raktim Kumar [2 ]
Kamatam, Sravani [2 ]
Banerjee, Arnab [3 ]
Gupta, Anjan [4 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Dept Internal Med, St Vincent Char Med Ctr, Cleveland, OH 44106 USA
[3] IPGMER, Kolkata, India
[4] Case Western Reserve Univ, Dept Cardiovasc Med, St Vincent Char Med Ctr, Cleveland, OH 44106 USA
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2017年 / 227卷
关键词：
Ranolazine; Angina; Diabetes; Atrial fibrillation; Pulmonary arterial hypertension; Diastolic dysfunction; CHRONIC STABLE ANGINA; MERLIN-TIMI; 36; ACUTE CORONARY SYNDROMES; PULMONARY ARTERIAL-HYPERTENSION; RANDOMIZED CONTROLLED-TRIAL; ONSET ATRIAL-FIBRILLATION; LATE SODIUM CURRENT; PRESERVED EJECTION FRACTION; MYOCARDIAL-INFARCTION; ISCHEMIC-HEART-DISEASE;
D O I：
10.1016/j.ijcard.2016.10.102
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Ranolazine was FDA approved for chronic angina in 2006. Since then, there has been extensive research involving this drug. The mechanism of action, debatable at the time of approval, has been demonstrated. Ranolazine acts via inhibition of late sodium channel current in the myocarclium. This acts by lowering abnormally high cytosolic calcium levels. Other possible clinical applications of Ranolazine have also been explored. Out of many lines of investigation, its effects in atrial fibrillation, especially post-CABG and recurrent atrial fibrillation show promise. It has also shown definite HbA1c lowering effects when used in diabetics with coronary artery disease. Other possible indications for the drug include pulmonary arterial hypertension, diastolic dysfunction and chemotherapy induced cardiotoxicity. This review aims to summarize major research regarding Ranolazine in potential applications beyond chronic angina. There are few dedicated large, randomized, phase III trials exploring the newer effects of Ranolazine. There are a few such Dials underway, but more are needed. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：556 / 564
页数：9
相关论文
共 71 条
[1]   Electrophysiologic basis for the antiarrhythmic actions of ranolazine [J].
Antzelevitch, Charles ;
Burashnikov, Alexander ;
Sicouri, Serge ;
Belardinelli, Luiz .
HEART RHYTHM, 2011, 8 (08) :1281-1290
[2]   Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: Results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial [J].
Arnold, Suzanne V. ;
McGuire, Darren K. ;
Spertus, John A. ;
Tang, Fengming ;
Yue, Patrick ;
Inzucchi, Silvio E. ;
Belardinelli, Luiz ;
Chaitman, Bernard R. ;
Kosiborod, Mikhail .
AMERICAN HEART JOURNAL, 2015, 170 (04) :753-+
[3]   Comparison of the Seattle Angina Questionnaire With Daily Angina Diary in the TERISA Clinical Trial [J].
Arnold, Suzanne V. ;
Kosiborod, Mikhail ;
Li, Yan ;
Jones, Philip G. ;
Yue, Patrick ;
Belardinelli, Luiz ;
Spertus, John A. .
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2014, 7 (06) :844-850
[4]   Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c [J].
Arnold, Suzanne V. ;
McGuire, Darren K. ;
Spertus, John A. ;
Li, Yan ;
Yue, Patrick ;
Ben-Yehuda, Ori ;
Belardinelli, Luiz ;
Jones, Philip G. ;
Olmsted, Ann ;
Chaitman, Bernard R. ;
Kosiborod, Mikhail .
AMERICAN HEART JOURNAL, 2014, 168 (04) :457-+
[5]   The Usefulness of Ranolazine for the Treatment of Refractory Chronic Stable Angina Pectoris as Determined from a Systematic Review of Randomized Controlled Trials [J].
Banon, David ;
Filion, Kristian B. ;
Budlovsky, Talia ;
Franck, Caroline ;
Eisenberg, Mark J. .
AMERICAN JOURNAL OF CARDIOLOGY, 2014, 113 (06) :1075-1082
[6]   Evaluation and treatment for angina in pulmonary arterial hypertension [J].
Barst, RJ .
AMERICAN JOURNAL OF MEDICINE, 2004, 116 (06) :427-428
[7]   Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine [J].
Belardinelli, L. ;
Shryock, J. C. ;
Fraser, H. .
HEART, 2006, 92 :6-14
[8]  
Burashnikov A, 2011, FUTUR CARDIOL, V7, P733, DOI [10.2217/fca.11.67, 10.2217/FCA.11.67]
[9]   Ranolazine improves insulin resistance in non-diabetic patients with coronary heart disease. A pilot study [J].
Caminiti, Giuseppe ;
Fossati, Chiara ;
Battaglia, Daniela ;
Massaro, Rosalba ;
Rosano, Giuseppe ;
Volterrani, Maurizio .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 219 :127-129
[10]   Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions [J].
Chaitman, Bernard R. .
CIRCULATION, 2006, 113 (20) :2462-2472
12345678